Hepatitis B virus (HBV) infection is a serious liver disease caused by the hepatitis B virus, posing a serious global health challenge. In 2022, it accounted for approximately 257 million cases worldwide, with an annual incidence of 1.5 million new cases. There is a high unmet clinical need for better therapies to treat the disease, as current treatment options, such as antiviral drugs and interferon therapy, have limitations. Furthermore, the growing focus on novel hepatitis B virus (HBV) infection therapeutics, including RNA interference, immunomodulators, and combination therapies, is likely to support pipeline growth in the coming years, improving patient outcomes.
The Hepatitis B Virus (HBV) Infection Drug Pipeline Insight Report by Expert Market Research provides comprehensive insights into hepatitis B virus (HBV) infection therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs in development for hepatitis B virus (HBV) infection. The hepatitis B virus (HBV) infection report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The hepatitis B virus (HBV) infection pipeline landscape includes an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with hepatitis B virus (HBV) infection treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to hepatitis B virus (HBV) infection.
Hepatitis B virus (HBV) infection is a viral disease that affects the liver, potentially leading to chronic conditions such as cirrhosis or liver cancer. It spreads through contact with infected blood, unprotected sex, and from mother to child during childbirth. The virus enters liver cells, replicates, and triggers an immune response, causing liver inflammation. It can be acute or chronic, with chronic infection posing long-term health risks that require continuous monitoring and management.
Hepatitis B virus (HBV) infection treatment focuses on suppressing viral replication and preventing liver damage. Antiviral medications such as Entecavir, Tenofovir, and interferon therapy help control the virus but do not cure it. For chronic cases, lifelong treatment may be necessary. Researchers are developing novel therapeutics, including RNA interference and immune-based therapies, to achieve a functional cure.
Hepatitis B Virus (HBV) infection remains a significant global health burden, with an estimated 257 million cases in 2022 and an annual occurrence of 1.5 million new infections. The United States has around 580,000 to 2.4 million cases, while the United Kingdom reported nearly 270,000 cases (0.6% of the population). India records approximately 40 million chronic HBV cases.
This section of the report covers the analysis of hepatitis B virus (HBV) infection drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II accounts for a major share of the total hepatitis B virus (HBV) infection clinical trials.
The drug molecule categories covered under the hepatitis B virus (HBV) infection pipeline analysis include small molecules, RNA therapeutics, monoclonal antibodies, gene therapies, biologic immunotherapies, and others. The hepatitis B virus (HBV) infection report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for hepatitis B virus (HBV) infection.
The EMR report for the hepatitis B virus (HBV) infection drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed hepatitis B virus (HBV) infection therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in hepatitis B virus (HBV) infection clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for hepatitis B virus (HBV) infection. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of hepatitis B virus (HBV) infection drug candidates.
Vemliver, an antiviral medication, is being evaluated in a Phase IV study sponsored by Daewoong Pharmaceutical Co. Ltd. to assess the efficacy and safety of switching from Entecavir in chronic hepatitis B patients. The study, expected to be completed by December 31, 2025, will enroll approximately 196 participants. It is designed to assess hepatitis B virus (HBV) antiviral inhibition and safety at 24 and 48 weeks.
Bepirovirsen, an investigational treatment for chronic hepatitis B, is being evaluated in a Phase 3 study sponsored by GlaxoSmithKline. The study aims to assess the drug's efficacy, safety, and durability in nucleos(t)ide analogue-treated participants, focusing on hepatitis B surface antigen (HBsAg) suppression. Expected to be completed by May 2026, it includes around 941 participants across multiple stages of treatment and follow-up.
GSK3965193, sponsored by GlaxoSmithKline, is being studied in a Phase 1/2a trial involving healthy participants and those with chronic hepatitis B virus (HBV) infection. This study aims to assess the safety, tolerability, and pharmacokinetics of GSK3965193, both alone and in combination with Bepirovirsen. The study is expected to be completed by October 2027, with an estimated enrollment of 132 participants.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Hepatitis B Virus (HBV) Infection Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for hepatitis B virus (HBV) infection. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into hepatitis B virus (HBV) infection collaborations, regulatory environments, and potential growth opportunities.
Global Hepatitis B Infection Treatment Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share